Summary The nuclear DNA content of 351 breast carcinomas was determined by flow cytometry from paraffin-embedded tissue to assess the prognostic significance of DNA ploidy, the DNA index (DI) and the S-phase fraction (SPF). The minimum follow-up of the patients was 22 years, and they were all from a defined urban population. DNA ploidy correlated with histological type and grade, mitotic count and nuclear pleomorphism (P<0.0001), and also with axillary nodal status (P=0.0005), tumour necrosis (P=0.001), primary tumour size (P = 0.03), menopausal status (P = 0.004) and the presence of distant metastases at the time of the diagnosis (P = 0.04). Survival corrected for intercurrent deaths of the patients with a diploid tumour was better than that of the patients with a non-diploid tumour (P = 0.0001, 48% vs 28% at 25 years). SPF Leatham & Brooks, 1987; Slamon et al., 1987).
; Leatham & Brooks, 1987; Slamon et al., 1987) .
The nuclear DNA content determined by flow cytometry has recently emerged as a new prognostic factor in breast cancer. The technique has gained some popularity, since flow cytometric histograms are rapid to produce and often easy to interpret. It has been suggested that breast carcinomas with an abnormal (non-diploid or aneuploid) nuclear DNA content are associated with less favourable prognosis than carcinomas with a normal (diploid) DNA content (Hedley et al., 1984 (Hedley et al., , 1987 Coulson et al., 1984; Ewers et al., 1984; Thorud et al., 1986; Baildam et al., 1987; Cornelisse et al., 1987; Kallioniemi et al., 1987; Stal et al., 1989) . Similarly, the DNA index (DI, the relative DNA content of an aneuploid stemline of cells as compared with diploid cells) and the percentage of S-phase cells in the DNA histogram (S-phase fraction, SPF) have been found by some to be of prognostic significance (Dowle et al., 1987; Hedley et al., 1987; Stal et al., 1989; McDivitt et al., 1986; Klintenberg et al., 1986) . However, the prognostic value of nuclear DNA content analysis is still unsettled. Some authors report DNA content to be the most important prognostic variable in breast cancer, and to have independent prognostic value in a multivariate analysis , whereas others find it to have prognostic value only in a univariate analysis (Stal et al., 1989; Hedley et al., 1984) , and yet a few fail to find any prognostic significance at all when overall survival is concerned (van der Linden et al., 1989; Uyterlinde et al., 1988; Owainati et al., 1987) . The series published have often been heterogeneous, comparison of ploidy with other prognostic variables selective and inadequate, and the follow-up times short. proportional hazard model (BMDP 2L). All P values are two-tailed.
Results

DNA ploidy
One hundred and eleven (32%) of the cancers were diploid (74 had a symmetrical and 37 as asymmetrical GI peaks), and 240 (68%) non-diploid (157 were aneuploid, 27 tetraploid and 56 multiploid). The distribution of DNA indices is shown in Figure 2 . The distribution is bimodal with peaks in the diploid/near diploid region, and in the hypertriploid/ tetraploid region. SPF ranged from 2.0 to 38.0%, median 9.0% (mean 11.6%, s.d. 7.9%).
Survival
The crude survival of all patients was 34% 10 years and 17% 25 years after the diagnosis, and the corresponding figures corrected for intercurrent deaths were 41% and 34%. Cor- rected survival of patients with diploid carcinoma was more favourable than that of the patients with non-diploid cancer (P = 0.0001). The 10-year survival of the patients with diploid cancer was 53%, and the 25-year survival 48%, whereas the corresponding figures for non-diploid cancer were 36% and 28% (Figure 3 ). There was no significant difference in survival between patients with aneuploid, tetraploid, or multiploid cancer.
After a series of calculations, the DI value 1.3 was found to have most prognostic significance as a cut-off value. Carcinomas with DI < 1.3 had more favourable prognosis than those with DI> 1.3 (P <0.0001, Figure 3 ). Carcinomas with > 7% S-phase cells were associated with inferior survival as compared with those with SPF <7% (P <0.0001 ( Figure 4) ; the cut-off point was found by serial calculations with different SPF values). If the cases in which SPF was calculated for the aneuploid stemline only were considered (DI > 1.3, n = 98), carcinomas with SPF > 13% had inferior prognosis (P = 0.04), and if the rest of the cases were analysed (DI < 1.3, n = 124), the best cut-off value was again 7% (P = 0.0007).
The prognostic influence of ploidy, DI and SPF after stratification according to the menopausal or axillary nodal status is shown in Table I . DNA ploidy and DI did not have prognostic significance in the axillary nodes positive group, whereas SPF was a significant prognostic factor in all patient groups studied.
Correlations with other prognostic factors Correlation of DNA ploidy, DI and SPF with several clinicopathological prognostic factors is shown in Tables II   and III . They show a strong correlation with many other factors, such as histological type and grade, tubule formation, number of mitoses, nuclear pleomorphism, the primary tumour size, extent of tumour necrosis, the presence of elastin, axillary nodal status and the presence of distant metastases at the time of the diagnosis.
Non-diploid DNA content was also associated with age at diagnosis, 74% of the post-menopausal and 59% of the premenopausal patients had non-diploid cancer (P = 0.004). The mean age at diagnosis of the patients with a non-diploid cancer was 56.2 years (s.d., 11.0 years), as compared with 53.9 years (s.d., 12.8 years) in patients with diploid cancer (P = 0.03). The patients with tetraploid cancer were older than those with aneuploid cancer at diagnosis (P = 0.006, the mean age of the tetraploid group was 62.4 years, and that of the aneuploid group 55.7 years), but the mean age of the patients with multiploid cancer and those with aneuploid cancer did not differ (P = 0.7).
DNA non-diploidy was associated with the clinical stage: 49%, 67%, 73% and 87% of the stage I, II, III and IV tumours, respectively, were non-diploid (P = 0.01). Only 21 
organs during the follow-up. However, carcinomas with DI< 1.3 were more often associated with severe inflammatory cell reaction than carcinomas with DI > 1.3 (P = 0.008), and also non-diploid carcinomas had such a tendency (P = 0.08). Carcinomas with SPF <7% were more often associated with principal intraductal growth pattern than those with SPF >7% (P = 0.05). If DNA ploidy, SPF and DI were tested together with the other factors after stratifying the material according to the axillary nodal status, the most important prognostic factor in axillary node negative patients was primary tumour size (P = 0.002), followed by type of tumour margin (P = 0.01) and SPF (P = 0.02); and in axillary node positive patients primary tumour size (P<0.001), histological grade (P = 0.001), type of tumour margin (P = 0.02), extent of tumour necrosis (P = 0.04) and SPF (P = 0.07). If the material was stratified according to the menopausal status, the most important prognostic factors in the premenopausal group were axillary nodal status (P<0.001), type of tumour margin (P = 0.01), mitotic count (P = 0.01), and tubule formation (P = 0.03); and in the post-menopausal group axillary nodal status (P <0.001), followed by histological grade (P<0.001), primary tumour size (P<0.001) and type of tumour margin (P = 0.02).
If crude survival was tested instead of corrected survival in Cox's analysis (and age at diagnosis was excluded from the tested variables), the relative significance of SPF, DI and ploidy was somewhat greater. SPF (P<0.001) was the third in rank after axillary nodal status (P<0.001) and primary tumour size (P<0.001) in relative importance, and the most important single factor (P = 0.002) in the axillary node cCut-off point 1.30. n.s., statistically not significant.
negative group (n = 104). If both SPF and age were excluded from the tested variables, DI with cut-off point 1.3 (P <0.001) became the most important variable predicting crude survival in the axillary node negative group (n = 158).
Discussion
A non-diploid nuclear DNA content, DI value > 1.3 and SPF> 7% were all correlated with adverse prognosis, and the adverse effect was shown to last for 25 years after the diagnosis. All these variables were associated with many of the known prognostic factors in breast cancer, some of which were more powerful prognostic factors than the ones derived from the DNA content analysis in multivariate analyses. To our knowledcge, there are no published studies in which DNA content determination has been attempted from paraffin embedded material that has been collected in the 1940 s and 1950 s. Although the number of uninterpretable histograms was the greater the older the sample was (data not shown), the majority of the histograms (89%) were of acceptable quality. The histograms were classified without knowledge of survival or clinicopathological data, and the correlations found were stronger than in many series produced from more recent material (Dressler et al., 1988; Feichter et al., 1988; Haag et al., 1984) . The percentage of nondiploid tumours found (68%) is almost identical to the mean percentage of 67% found in 23 studies on breast cancer comprising the total of 5,785 patients (data not shown).
Although DNA flow cytometry has been claimed to be an objective method, the DNA histograms are not always similarly interpreted, resulting in a different percentage of DNA aneuplody found even if the data is similar (Joensuu & Kallioniemi, 1989) . The use of DI abolishes some of the problems involved in data interpretation, since near diploid tumours and tumours with a small DI may be grouped together with the diploid tumours. DI is easy to calculate, and was a slightly more powerful prognostic variable than DNA ploidy (Table IV) . The great majority of non-diploid tumours have DI> 1.3 (Figure 2 ) and hence both DI> 1.3 and DNA non-diploidy are closely related variables ( Figure  3) .
The SPF value 7% was the most effective cut-off percentage for prognosis. The value of SPF as a prognostic factor is lessened by the fact that it often cannot be reliably assessed, e.g. in cases with overlapping cell populations or presence of cell debris. When SPF of diploid histograms is calculated, a variable number of stromal and non-tumour cells are included usually reducing the relative percentage of SPF, whereas if SPF is calculated from an aneuploid stemline, only cancer cells are considered, and SPF is likely to be higher. In this series only 17% of non-diploid tumours had SPF <7% as compared with 72% of the diploid tumours, which difference may partly be technical. Hence, SPF is also related to DNA ploidy and DI.
Most authors agree that DNA aneuploidy is associated with poor histological grade (Thorud et al., 1986; Moran et al., 1984; Spyratos et al., 1987; Olszewski et al., 1981; Jakobsen et al., 1984; Hedley et al., 1984; McDivitt et al., 1986; Kute et al., 1985; Kallioniemi et al., 1987; Feichter et al., 1988; Dowle et al., 1987) , and the mitotic count, nuclear pleomorphism and degree of tubule formation describe much the same thing. The amount of elastin and the extent of necrosis have been associated with histological grade too (Fisher et al., 1984; Kuhajda et al., 1985) . The association of ploidy with primary tumour size and axillary nodal status has been controversial (Uyterlinde et al., 1988; Spyratos et al., 1987; Taylor et al., 1983; McDivitt et al., 1986; Cornelisse et al., 1987; Dressler et al., 1988) . In this series DNA aneuploidy was significantly more common in large primary tumours, and in tumours with axillary or distant metastases (Table II) . It has previously been largely unnoticed that the type of tumour margin is an important prognostic factor in both uni-and multivariate analyses, and this feature has quite unexpectedly no correlation with the DNA analysis derived factors.
The occurrence of aneuploidy in histological subtypes of breast cancer has received scant attention; only mucinous carcinomas have been extensively studied (Toikkanen et al., 1988) . The percentage of non-diploid tumours was high in medullary (86%) and ductogenic NOS (74%) carcinomas, and low in lobular (43%) and tubular (40%) carcinomas (Table II) . Survival of the patients with lobular carcinoma, or with carcinoma of the other special types, was much better than that of the patients with a ductogenic infiltrating NOS carcinoma (P<0.0001). The medullary carcinoma, however, was associated with a favourable outcome despite frequent aneuploidy and, by definition, poor histological differentiation. The good prognosis of medullary carcinoma appears to depend on factors not associated with the ordinary favourable histological features, and it may be associated with its definite circumscription and strong lymphocyte infiltration (Hsu et al., 1981) .
As in several other cancers (Joensuu et al., 1986; , and even in benign tumours , patients with a non-diploid breast tumour were older than those with a diploid tumour (Table II) . This has also been noticed by Taylor et al. (1983) . DNA aneuploid tumours usually have hypertriploid DNA content, and it has been suggested that DNA aneuploidy develops via tetra-ploidy: tetraploid tumours lose some of their chromosomal material resulting in hypertriploid nuclear DNA content (Ewers et al., 1984) . However, patients with tetraploid cancer were older at diagnosis than patients with aneuploid carcinoma (P = 0.006), which is poorly compatible with this theory.
As expected, the ability of most of the factors listed in Table IV to predict the final outcome decreased if crude survival was studied instead of survival corrected for intercurrent deaths (P values became larger). However, the opposite was true for age at diagnosis, and unexpectedly for DI and SPF. Because special attention was paid to finding the correct cause of death, deaths caused by breast cancer misinterpreted as intercurrent deaths are not a likely explanation for the stronger correlation of DI and SPF with crude than with corrected survival. It is rather a further piece of evidence for the association of advanced age and the tendency to develop non-diploid solid tumours.
Most authors (Thorud et al., 1986; Coulson et al., 1984; Hedley et al., 1987; Kallioniemi et al., 1987; Dowle et al., 1987; Cornelisse et al., 1987; Ewers et al., 1984; Stal et al., 1989) , but not all (van der Linden et al., 1989; Uyterlinde et al., 1988; Owainati et al., 1987) , agree that DNA aneuploidy is associated with unfavourable survival in breast cancer. In most studies this association has, however, been weak. Cornelisse et al. (1987) found only a slight correlation with ploidy and overall survival (P = 0.04) despite having the largest histologically verified material published so far (n = 565). Contrary to our results, ploidy had no effect on survival in the axillary node negative group, and it had an independent impact on survival in the post-menopausal axillary node positive group. Still others have found ploidy to be significant in a univariate analysis, but not in a multivariate analysis (Hedley et al., 1984; Stal et al., 1989) . The most promising results have been published by Kallioniemi et al. (1987) , who found DNA ploidy to be an independent prognostic factor, even if survival was controlled for nodal status.
The results of different studies must be compared with caution, since differences in histogram analysis, patient materials, follow-up and statistical analyses may be considerable. Unlike in most previous studies, the present series comes from a defined well-documented population, and includes all breast cancers in this area without any selection. The number of clinicopathological factors studied exceeds that of the previous works, which may have significance, because the exclusion of any major prognostic factor from the Cox's analysis may influence the result. However, steroid receptor analyses were not available to us.
It is concluded that DNA ploidy, DI and SPF are important prognostic factors in breast cancer, especially in axillary node negative cancer and in post-menopausal patients, and that they have long-term prognostic influence. However, they are closely associated with other histological and clinical prognostic factors related to cancer morphology, differentiation, tumour size and spread. SPF could be shown to have independent prognostic value in multivariate analyses, but axillary nodal status, size of primary tumour, histological grade and type of tumour margin were more powerful independent prognostic factors. DNA ploidy and DI have prognostic value as single variables in axillary node negative patients, whereas SPF has such value both in axillary node negative and positive patients.
